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The incidence of congenital heart defects is 0.8% of 
liveborn infants. Of these, 8 % to 13 % are ostium se- 
cundum atrial septal defects, which can be success- 
fully repaired by open heart surgical techniques with 
a low (<l % ) mortality rate. However, morbidity as- 
sociated with cardiac surgery is universal, and resid- 
ual scar is present in all. A less invasive method of 
repairing atrial septal defects, sparing patients the 
discomfort and morbidity of open heart surgery, 
would be advantageous if its mortality and compli- 
cation rates were similar to or less than the surgical 
method. Pioneering works of King et al.lm3 and Rash- 
kind4-6 have explored the potential of transcatheter 
methods of closure of atrial defects in replacing open 
heart surgery and have laid a foundation on which 
other transcatheter methods can be developed and 
refined. The initial devices used for atrial septal de- 
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feet closure were modified by Rashkind and by Lock 
et al7 A different type of device was introduced by 
Sideris et al8 The purpose of this communication is 
to present our international experience with the but- 
toned device in closing atria1 septal defects and to 
evaluate the feasibility, safety, and effectiveness of 
this method of closure. 
METHODOLOGY 
After they gave informed consent, patients with 
secundum atrial septal defects were selected for 
transcatheter occlusion according to rules regulating 
custom-made devices in each country, including the 
United States. The study protocol for human use of 
the custom-made devices was approved by the Hu- 
man Subjects Committee (Institutional Review 
Board) of each institution. Occlusions were per- 
formed at 16 institutions (Table I). Of the 180 tran- 
scatheter atria1 septal defect occlusions performed 
during a 4.5-year period ending February 1993,130 
occlusions were performed under this protocol. The 
other 50 closures were performed at three U.S. insti- 
tutions (University of Arizona, University of Michi- 
gan, and University of Wisconsin) under a Food and 
Drug Administration (FDA)-supervised clinical trial 
with investigational device exemption. The number 
of subjects at each institution varied between 2 and 
25 patients. 
Patient inclusion/exclusion criteria. Patients were 
selected on the basis of standard criteria established 
for selection of patients for surgical closure of atrial 
septal defects.g Only patients with clinical and labo- 
ratory data, including echo-Doppler studies, suggest- 
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Table I. Institutions and investigators participating in Table Ill. Protocol for transcatheter occlusion of atria1 sep- 
atria1 septal defect occlusion clinical trial tal defects with buttoned device 
1. Ali Sham’s University Hospital, Cairo, Egypt (Ihab M. At- 
tia, MD) 
2. Athenian Institute of Pediatric Cardiology Athens, Greece; 
Custom Medical Devices, Amarillo, Texas (Eleftherios B. 
Sideris, MD) 
3. Batra Hospital & Medical Research Center, New Delhi, In- 
dia (Rajeev Lochan, MD) 
1. Premeditation with sedative mixture. General anesthesia 
was used in 18 patients in whom transesophageal echocar- 
diographic monitoring was used. 
2. Complete cardiac catheterization via percutaneous femoral 
venous route: (A) to exclude other cardiac defects, (B) to 
determine location of defect, and (C) t,o probe all pulmo- 
nary veins from left atrium. 
4. Cardiothoracic Center, Monaco (Francois Bourlon, MD) 
5. Centre Chirurgical Mario-Lallelongue, Paris, France (Jean 
Losay, MD) 
6. German Heart Center, Berlin, Germany (Gerd Hausdorf, 
MD) 
3. Balloon sizing of atria1 septal defect.‘“-‘” 
4. Selection of device 15 to 20 mm larger than stretched atrial 
defect diameter; table of device sizes (Table V), developed 
on basis of concepts detailed elsewhere,14 nerved as guide in 
device selection. 
7. Hospital do Coracle de RibeirBo Preto, Ribeirlo Preto, 
Brazil (Jorge Haddad, MD) 
5. Placement of femoral arterial line for monitoring systemic 
pressure during procedure. 
8. Hospital Cardiologique, Lille CBdex, France (Christian Rey, 
MD) 
9. G. B. Pant Hospital, New Delhi, India (Mohamed Khali- 
lullah, MD) 
10. San Donato Milaneze, Milan, Italy (Eustaquio Onorato, 
MD) 
6. Heparin 100 U/kg, maximum 3000 Units, intravenously. 
7. Femoral venous catheter/sheath was replaced with long 8F 
sheath (Cordis Corp., Miami, Fla.). For 45 and 50 mm de- 
vices, 9F sheath was used. Tip of sheath was positioned in 
mid left atrium. 
8. Occluder component of device was folded and introduced 
11. University of Arizona Hospitals, Tucson (Thomas R. Lloyd, 
MD) 
12. University of Freiburg, Germany (R. Mocellin, MD) 
13. University of Michigan Hospital, Ann Arbor (Robert H. 
Beekman, MD) 
14. University of Missouri Hospital, Columbia (Zudhi Lababidi, 
MD) 
15. University of Nancy, Nancy, France (Ann Marie Worms, 
MD) 
16. University of Wisconsin Hospital and Clinics, Madison (P. 
Syamasundar Rao, MD) 
9. 
10. 
into sheath. An 8F end-hole catheter (pusher) was inserted 
over loading wire into sheath and advanced, pushing oc- 
eluder toward left atrium. Occluder was delivered into left 
atrium under fluoroscopic (Fig. 10) and/or echocardio- 
graphic (Fig. 3) guidance. Occluder springs open and as- 
sumes its original shape. Occluder was aligned with atria1 
septum, and care was taken to avoid other structures. 
Pusher catheter was removed. Counteroccluder was 
threaded over loading wire (through rubber piece, button- 
hole) and positioned within sheath. Pusher catheter was 
reintroduced, and counteroccluder was delivered into right 
atrium. 
Table II. Modification of first-generation device 
1. Strengthening and redesigning of “button loop.” Instead of 
silk, 4 lb proof nylon was used. 
2. “Button” was made radiopaque by incorporating piece of 
Teflon-coated wire within “button.” 
3. Loading system was strengthened by replacing double thread 
in loading wire with 4 lb proof nylon. 
4. Thinner %-inch foam replaced l/s -inch polyurethane foam. 
ing the need for surgical correction were chosen. 
Two-dimensional echocardiographic views of the 
atria1 septum in multiple views (Fig. 1) were obtained 
to evaluate for presence of septal margins adequate 
to support the device. Assessment of adequacy of the 
septal rims is arbitrary and is at the discretion of the 
investigators at each of the institutions. At the time 
of cardiac catheterization, patients with a pulmo- 
nary-to-systemic flow ratio of <1.5 were excluded. 
Stretched diameter of the atria1 septal defect was 
measured by balloon occlusionlo-l3 in each case; pa- 
tients with stretched diameter >25 mm were also ex- 
cluded. Twelve adult patients with cerebrovascular 





Introduction of 1 mm knot of occluder (button) through 
rubber piece (buttonhole) of counter-occluder is performed 
by simultaneously gently pulling occluder against atria1 
septum and advancing counteroccluder with tip of long 
sheath. Verification that knot has been pulled through but- 
tonhole was obtained by fluoroscopy with aid of radiopaque 
marked on knot. Radiopaque wire of counteroccluder was 
positioned past radiopaque button (Fig. 10, C and D). Veri- 
fication of atrial septal defect occlusion was assessed by 
echo Doppler studies (Fig. 5). 
Loading wire was cut at tip and withdrawn, leaving two 
nylon strands holding device. Device was disconnected by 
pulling one of two nylon strands, thus disconnecting im- 
planted device from loading system. During both maneu- 
vers, tip of sheath was gently pressed against device to pre- 
vent application of excessive force on device, thereby pre- 
venting inadvertent dislodgment of device. 
Fifteen minutes after device implantation, blood samples 
for measuring oxygen saturations from main pulmonary 
artery, superior vena cava, and femoral art,ery were ob- 
tained, and main pulmonary artery cineangiogram was per- 
formed, in 80 of 180 patients. 
Three doses of Cefazolin (50 mg/kg/day) were administered 
to all subjects; first dose was given intravenously in cathe- 
terization laboratory, second and third doses were given 6 
and 12 hours after first dose. 
Aspirin 5-10 mg/kg/day by mouth was given starting day 
after device implantation. Aspirin was discontinued 6 to 12 
weeks later. 
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Fig. 1. Selected video frames of two-dimensional echographic images of atrial septum in multiple views 
to demonstrate atrial septal rim. a, Apical, four-chamber; b, subcostal, long-axis; C, precordial, short-axis; 
and d, subcostal, short-axis views are shown. Arrows, Atrial septal defect. Note good-sized margins in each 
view. Patient is good candidate for transcatheter closure. Ao, Aortic; LA, left atrium; LV, left ventricle; RA, 
right atrium; R V right ventricle. 
via an atria1 septal defect or patent foramen ovale 
were included, irrespective of the level of shunt. 
The device. The device (Fig. 2) consists of three 
components, an occluder, a counter occluder, and a 
delivery system, and has been described previous- 
ly. 8, 14-16 Modifications of the first-generation device 
are listed in Table II, and changes in the second-gen- 
eration device are shown in Fig. 2. 
Device implantation. The procedure of device im- 
plantation across the atrial septum is detailed in our 
previous reports,14-17 outlined in Table III, and 
shown in Fig. 3. 
Follow-up. Clinical evaluation, chest roentgeno- 
gram, and echo Doppler studies were performed 1 
day and 1,6, and 12 months after the occlusion and 
yearly thereafter. Clinical evaluation focused on 
symptoms and physical findings of a residual atria1 
septal defect. Chest roentgenograms were examined 
for device displacement and wire fractures. Echo 
Doppler studies were used to assess right ventricular 
volume overload (as defined in Table IV), position of 
device, and residual shunts. Shunts were quanti- 
tated, as outlined in Table IV. Additional abnormal- 
ities, if any, were also recorded. 
Data analysis. Data are expressed as mean k SD for 
continuous, normally distributed variables. Median 
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Fig. 2. Second- and third-generation buttoned devices. Second-generation device consists of occluder 
(0~) and counteroccluder (COc). Occ is composed of x-shaped wire skeleton covered with %-inch poly- 
urethane foam. A 2 mm string loop is attached to center of occluder. Loop is closed with knot made radio- 
paque. This radiopaque button (ROB) can easily be visualized on fluoroscopy. Folded 0.008 inch nylon tread 
(NT) is passed through hollow loading wire (L W) after having passed through loop in center of occluder. 
Counter-occluder consists of single-strand, Teflon-coated, wire skeleton covered with rhomboid-shaped 
polyurethane foam with rubber piece (RF’) sutured in its center. Third-generation device modification is 
introduction of additional loop immediately below radiopaque button. This will convert eccentric button 
of second-generation device to be aligned straight, thus making it easier to button occluder and counteroc- 
eluder across atria1 septum. 
values and ranges are given for data with skewed dis- 
tribution. Comparisons between preocclusion and 
postocclusion values were made by two-tailed, paired 
t test, and comparisons between groups were per- 
formed by analysis of variance. Categoric variables 
were compared by using chi-squared tests (for exam- 
ple, Fisher exact and McNemar’s). When multiple 
comparisons were made, the Bonferroni correction 
was applied. Actuarial analysis of event-free rates 
and rates of resolution of residual shunts were carried 
out by means of the Kaplan-Meier method. The level 
of statistical significance was set at p < 0.05. 
OBSERVATIONS 
Patients. During a 4.5-year period ending February 
1993,200 patients underwent cardiac catheterization 
to confirm the clinical diagnosis, to balloon-size10-13 
the atria1 septal defect, and to consider transcatheter 
occlusion. Occlusion was not attempted in 10 patients 
either because of a small (pulmonary-to-systemic 
flow ratio <1.5:1) shunt (1 patient) or because of a 
large (stretched diameter >25 mm) defect (9 pa- 
tients; Fig. 4). In seven other patients, the occluder 
component was delivered into the left atrium, but the 
occluder was pulled through the defect (either inad- 
vertently or because of a presumably large defect). 
The devices were retrieved via the venous sheath in 
six patients or by femoral vein cut-down in two pa- 
tients. In three patients the device was buttoned 
across the atria1 septum but, the investigator be- 
lieved the device to be unstable or to have caused an 
increase in right-to-left, shunt; therefore the device 
was withdrawn and retrieved out of the patient (1 via 
the sheath, 1 by femoral venous cut-down, and 1 by 
surgery). The remaining 180 (90%) patients under- 
went transcatheter occlusion. The patients’ ages 
ranged between 0.6 years and 76 years, with a median 
age of 7 years, with 61 children below <5 years and 
36 adults >20 years. The weight of these patients 
ranged between 3.6 and 105 kg, with a median of 22 
kg. Fifteen of the 180 patients have previously been 
reported.14-17 Fifty occlusions monitored by the FDA 
in three U.S. centersI are also included in this report. 
Size of the atrial septal defect. The atrial septal de- 
fect, was measured in the subcostal viewsI l3 during 
the echo Doppler study before transcatheter occlu- 
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Fig. 3. Selected video frames of apical four-chamber two-dimensional views of atria1 septum during de- 
vice implantation. Occluder is shown after its release in left atrium (LA) (open arrows) in a-d as it is slowly 
withdrawn toward atria1 septum. Solid arrowhead, Loading wire; LV, left ventricle; RA, right atrium; RV, 
right ventricle. 
sion. The echographic size of the atria1 septal defect 
was 10.6 + 3.8 mm, with a range of 5 to 24 mm. In the 
patients with left-to-right shunting across the atria1 
septal defect (n = 168), the pulmonary-to-systemic 
flow ratio was 2.1 rt 0.6; the range was 1.5 to 3.8. 
Stretched diameter measured by balloon-sizing is 
generally larger than the echocardiographic measure- 
ment12f l3 and was 15.8 + 4.6 mm, with a range of 5 
to 25 mm. 
Device implantation. Successful implantation of the 
device across the atrial septal defect was accom- 
plished in 166 (92 % ) of 180 patients in whom the de- 
vice was released or 166 (83 % ) of 200 patients taken 
to catheterization laboratory with the intent to 
occlude the defect (Fig. 4). The outcome of the 
unsuccessful implantations will be described later. 
The first-generation device was used in the initial 9 
patients. The modified (Table II and Fig. 2), second- 
generation device was used in 106 patients, and a 
third-generation device with an additional loop (Fig. 
2) was used in the remaining 65 patients. The size of 
the devices used varied between 25 and 50 mm: 25 
mm devices were used in 10 patients; 30 mm in 31; 35 
mm in 50; 40 mm in 52; 45 mm in 19; 50 mm in 13, 
and miscellaneous sizes in the remaining 5. An 8F 
sheath was used for delivery of 148 of the devices and 
a 9F sheath for the remaining 32 devices. 
Immediate results. In 166 of 180 implantations, the 
atria1 defects were effectively occIuded as demon- 
strated by (1) decrease in pulmonary-to-systemic 
flow ratio by oximetry from 2.1 f 0.6 to 1.05 + 0.1 
(p < 0.01) in 80 patients in whom such data were 
available; (2) normalized Ss and disappearance of 
middiastolic murmur by auscultation (n = 166); and 
(3) improvement in right ventricular volume over- 
loading by echocardiogram (n = 166). 
Oxygen saturation data obtained after device 
implantation was available in 80 patients; the pul- 
monary-to-systemic flow ratio was 1.0 in all but 12 
patients. Those 12 had a pulmonary-to-systemic flow 
ratio of 1.3 + 0.2, with a range of 1.1 to 1.7; median 
was 1.2. Levophase of the pulmonary artery cinean- 
giogram was evaluated in all these 80 patients. Small 
atria1 shunts were observed in only 12 patients, the 
same patients with demonstrable shunt by oximetry. 
Echo Doppler studies performed after device im- 
plantation in all patients in whom the implant was 
successful revealed a well-positioned device across 
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No defect by two-dimensional 
echo 
No color Doppler disturbance 
on right atrial side of device 
No RV volume overload* 
No defect by two-dimensional 
Small 
echo 
Minimal color disturbance on 
right atrial side of device (<l 
mm width at origin of color 
Doppler jet) 
No RV volume overload* 
No defect by two-dimensional 
echo 
1 to 2 mm width of color Dop- 
pler jet, either in center or on 
periphery of device 
No RV volume overload* 
Moderate 
Large 
Defect visualized on two-dimen- 
sional echo 
>2 mm width of color jet 
RV volume overload* may be 
present 
Defect visualized by two-dimen- 
sional echo 
Large and/or multiple color 
Doppler jets 
RV volume overload* 
RV, Right ventricle. 
*RV volume overload is defined as enlarged RV (>95th percentile for pa- 
tient’s body surface area) and flat to paradoxic interventricular septal mo- 
tion. 
the atria1 septal defect (Fig. 5). In 92 (55%) patients 
(n = 168; 166 successful implantations plus 2 unbut- 
tonings that occurred later) no residual shunts were 
observed (Fig. 5). In the remaining 76 (45 % ) patients, 
62 trivial, 11 small, and 3 moderate shunts could be 
detected by color Doppler flow studies (Table IV). 
When effective occlusion (by echo Doppler criteria) 
is defined as trivial or no residual shunt along with 
resolution of right ventricular volume overload, 154 
(92%) of 168 had effective occlusions. 
Complications. Significant complications include 
unbuttoning, whole-device embolization, and atria1 
perforation. Unbuttoning was the most common 
complication and occurred in 13 (7.2%) of cases. 
Whole-device embolization occurred once (0.6%). 
Ten of these 14 events occurred while the patients 
were in the catheterization laboratory; in the other 4, 
device dislodgment was discovered 4 hours, 24 hours, 
1 week, and 4 weeks later, respectively. The patients 
remained hemodynamically stable. Transcatheter 
retrieval of the device was accomplished in four pa- 
tients, who underwent elective surgical correction of 
Fig. 4. Flow chart of patients taken to catheterization 
laboratory with intent to close atria1 septal defect (ASD). 
Qp:Qs, Pulmonary-to-systemic flow ratio; TIA, transient 
ischemic attack. 
their atria1 septal defect at a later date. Surgical clo- 
sure of the atria1 defect, along with extraction of the 
dislodged device, was performed in the remaining 10 
patients. Nine of these devices (occluders) were in the 
left atrium, and their retrieval did not add to the op- 
eration. Pulmonary arteriotomy was required in one 
patient with whole-device embolization into the main 
pulmonary artery. Eight counteroccluders were em- 
bolized into the pulmonary artery and five into the 
right atrium. Seven of the 13 were retrieved at 
surgery, 4 transvenously, and 2 were left alone 
because they were not obstructive by pressures and 
angiography. There were no deaths. Three of the 14 
device dislodgements have been mentioned in previ- 
ous publications.14p 16, ig 
Twelve of the 13 device unbuttonings occurred 
during the initial experience of the investigators, in- 
dicating a learning curve. When initial experience is 
defined as the first 10 cases for each investigator, 12 
(9.9 % ) unbuttonings were found among 121 patients. 
This is higher than that seen with investigators hav- 
ing greater experience (L 10 cases) in device implan- 
tation, that is, l(l.7 % ) in 59 (p = 0.06), although this 
did not attain preset statistical significance. Simi- 
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Fig. 5. Two-dimensional and color Doppler images of atria1 septum obtained from apical view immedi- 
ately after device implantation. Note good position of occluder (Occ) and counter occluder (COcc) (on end) 
across atria1 septum (a). There was no evidence for shunt by color Doppler (b). LA, Left atrium; RA, right 
atrium. 
larly, the influence of improvement with successive 
generations of the device on the prevalence of un- 
buttonings is examined in Fig. 6. There is no signif- 
icant difference (p = 0.99) in the prevalence of un- 
buttoning between first and second generations of 
the devices. There is an apparent decrease in unbut- 
toning after the introduction of the third-generation 
device, but this also did not attain statistical signif- 
icance (p = 0.135). 
Atria1 perforation occurred twice, both times re- 
lated to rough manipulation of the device by new 
investigators. In one case there was chest pain and 
evidence for small hemopericardium by echocardi- 
ography. The patient was operated on electively 1 
month later. In the second patient, the atria1 perfo- 
ration was not clinically evident and was an inciden- 
tal finding during surgery for device malposition and 
residual shunt. 
Minor complications included transient arrhyth- 
mias (atria1 extrasystoles, sinus tachycardia, and 
atria1 fibrillation in one adult patient) and trivial mi- 
tral (rz = 3) or tricuspid (n = 2) insufficiency detected 
by color Doppler echocardiography. In two of our 
patients, atrioventricular valve insufficiency may be 
related to close proximity of a device arm to valve 
leaflets. Right-sided entry of air bubbles (microcav- 
itations) was seen by echocardiography during device 
implantation in a few cases. In one patient there was 
significant air entry into the right heart with a tran- 
sient drop in blood pressure. There were, however, no 
neurologic sequelae. 
Follow-up. Follow-up clinical, chest x-ray, and echo 
Doppler studies are available in all patients in whom 
successful device implantation has been accom- 
plished. The follow-up duration varied between 1 
month and 4 years, with a median of 12 months. Fol- 
low-up was available at 1,6, and 12 months after de- 
vice implantation in 164, 141, and 107 patients, 
respectively. Very few patients had follow-up data 
longer than 1 year after implantation; therefore fol- 
low-up results beyond 1 year were excluded from 
further analysis. Clinical, chest x-ray, and echo Dop- 
pler data were available in each patient at each fol- 
low-up interval indicated. In two patients devices 
were explanted and atria1 defects closed because of 
significant residual shunts 3 and 9 months after im- 
plantation, respectively. Because of reports of break- 
age of wire hinges at follow-up after implantation of 
the Bard Clamshell Septal Umbrella (USCI, Biller- 
ica, Mass.),20* 21 we specifically examined the chest 
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Fig. 6. Prevalence of unbuttonings with each generation of device during its evolution. Note that there 
is no significant (p = 0.99) difference between first- and second-generation devices. Although prevalence 
of unbuttonings appears to be less with third-generation device, this difference did not attain statistical 
significance (p = 0.135). 
roentgenograms for this complication. No wire frac- of volume overloading and decrease in the size of the 
tures or migration of the radiopaque device compo- right ventricle. Two-dimensional echocardiography 
nents were observed except in two patients in whom revealed stable position of the device. Color flow- 
wire distortion was noted at the 6-month follow-up mapping studies showed a tendency for the residual 
visit. In one of these the core wire was embolized into shunts to become smaller and disappear. There was 
the axillary artery and was extracted via a small in- a reduction of small shunts to trivial and trivial to no 
cision with the patient under local anesthesia. At the shunts. The incidence and magnitude of residual 
discretion of the primary cardiologists caring for shunts are shown in Fig. 8. There is a gradual increase 
these two patients, surgery was performed. In both in the percentage of subjects without residual shunts, 
patients the device was found to be completely and the magnitude and prevalence of residual shunts 
endothelialized; the surgeon removed the wires and gradually decreased with increasing follow-up dura- 
left the device in place. These two patients had the tion. Although there was no statistically significant 
device implanted in the fall of 1992 from a single difference between day 1 and l-month follow-up 
batch of devices manufactured in the fall of 1992. The (p = 0.62), there was a significant decrease in the 
problem was traced to a defective processing tech- prevalence of residual shunt 6 months (p = 0.003) 
nique that has been rectified without recurrence of and 12 months (p <O.OOl) after device implantation 
the problem. Actuarial event-free (surgical interven- (Fig. 8). Rates of resolution of residual shunts present 
tion for atrial perforation or removal or inspection of immediately after device placement are shown in Fig. 
the device with or without closure of the atria1 defect 9. Fifteen unselected patients with trivial shunts by 
is considered an event) rates are shown in Fig. 7. In color Doppler studies underwent cardiac catheter- 
the remaining patients there were no residual mur- ization 6 to 12 months after device implantation. No 
murs indicative of an atria1 septal defect, and the shunts were demonstrated by oximetry in 12 pa- 
second heart sound was normal. M-mode echo- tients. In three patients shunts were small, with a 
graphic images suggested continued disappearance pulmonary-to-systemic flow ratio of 1.1 to 1.2. 
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MONTHS FOLLOWING DEVICE IMPLANTATION 
Fig. 7. Graph shows actuarial event-free rates after transcatheter occlusion of secundum atrial septal de- 
fect with buttoned devices. 
60- 
20 - 
0-r 7 r 
NiSM NTSM NTSM NTSM 
1 Day 1 Month 6 Months 12 hbnths 
Fig. 8. Incidence of residual shunts after transcatheter occlusion of secundum atrial septal defects. Mc- 
Nemar’s test for pairwise comparisons of data was used. To adjust for multiple comparisons, 0.05/3 = 0.017 
was used as level of significance for each comparison. There was no significant difference (p = 0.62) between 
1 day and 1 month. However, there was significant reduction in residual shunt at 6 months @ = 0.003) and 
12 months (p < 0.001) after device implantation when compared to those at 1 day after implantation. N, 
No shunt; T, trivial shunt; S, small shunt; M, moderate shunt. 
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Fig. 9. Actuarial resolution of residual shunts for patients who had shunts 1 day after device placement. 
No recurrence of paradoxic embolism was observed 
in the 11 of 12 patients in whom the atria1 defect was 
closed to prevent further episodes of cerebrovascular 
accidents. In one patient, transient ischemic attack 
(focal neurologic deficit without a corresponding le- 
sion on computed tomographic scan) was suspected. 
In this patient transesophageal echo contrast study 
demonstrated residual right-to-left shunt. Surgical 
closure of the residual defect was performed at the 
discretion of the primary cardiologist. This patient 
was included in the event-free survival curve de- 
picted in Fig. 7. Transesophageal contrast study with 
Valsava was performed in seven other patients 6 
months after device implantation. No residual right- 
to-left shunt was observed in these patients. No ep- 
isodes of endocarditis or thrombus formation (by 
means of patient history and by two-dimensional 
echographic scans of the device and atrial septum) on 
the device were observed in any patient. 
Twenty patients underwent surgery (14 device 
dislodgements, 3 residual shunts and/or atria1 perfo- 
ration, 2 device inspections for wire distortion, and 1 
paradoxic embolism) a few hours to 9 months after 
device implantation (Fig. 4). Surgery was uneventful 
in all these patients. Follow-up 3 months to 3 years 
after surgery was available in 16 patients. All were 
without symptoms and significant cardiovascular 
abnormality. 
COMMENTS 
Buttoned device for atriai septal defect occlusion. 
The first atria1 septal defect occlusion by the but- 
toned device was performed in September 1988. Nine 
implantations were performed with the first-genera- 
tion device; most have been described elsewhere.14-i7 
The major problems with the first-generation device 
were inability to recognize adequate buttoning and 
difficulty in withdrawal of nonimplanted devices. 
Modifications of the retrieval system made percuta- 
neous retrieval of nonimplanted devices possible. In- 
deed, all nonimplanted second-generation devices 
were extracted transvenously. Moreover, the follow- 
ing improvements were made to the method. (1) 
Withdrawing a balloon catheter under fluoroscopy 
and color flow-mapping improved the method of siz- 
ing the defect. Multiple or irregular defects could 
therefore be assessed by this technique. (2) Tables 
with the optimal device selection for each defect size 
were established (Table V). (3) Good quality fluoros- 
copy and echocardiography with color flow mapping 
were used to guide the device. Fluoroscopy should be 
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Fig. 10. Selected cineradiographic frames of device during and after implantation of device across atrial 
septal defect. A, Occluder (Occ) is delivered into left atrium. Four-chamber view of heart is shown. Radio- 
paque marker on “button” (B), loading wire CL W), and sheath (S) through which occluder had been de- 
livered are shown. B, Counter-occluder (COc) is delivered into right atrium past button. Loading wire and 
sheath are also shown. C, Anteroposterior view of B. D, Device is disconnected from wire. Occluder, coun- 
teroccluder, and button are shown in four-chamber view. Catheter (C) is in right ventricle. 
Table V. Stretched atria1 septal defect sizes and recom- 












sensitive enough to demonstrate the skeleton wires, 
radiopaque button, and catheters and sheaths used 
(Fig. 10). Good quality echocardiography and color 
flow mapping can be achieved by means of the tran- 
sthoracic approach in small children, but the transe- 
sophageal approach is preferable in older children 
and adults. (4) The investigators were instructed to 
manipulate the occluder in the left atrium to achieve 
effective occlusion, alignment with the atria1 septum, 
and noninterference with other structures. 
Residual shunts. The significance of the relatively 
high incidence of trivial residual shunts by color flow 
mapping immediately after implantation is not 
known but is not alarming because (1) there was no 
clinical evidence of a shunt (no murmurs, a normally 
moving second heart sound); (2) right ventricular 
volume overload by echocardiography improved; (3) 
there is experimental data that the device is well-en- 
dothelialized if properly positioned on the atrial sep- 
turns81 22; (4) there is evidence in our data from the 
FDA trialI and with the clamshell device23 that most 
of the initial trivial shunts tend to become smaller or 
disappear. 
Indications. The major indication for the buttoned 
device atria1 septal defect occlusion was management 
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of left-to-right shunts. However, a few patients with 
small right-to-left shunts or previous strokes also had 
successful occlusions. Because the occluder of this 
device is on the left atria1 side, it is reasonable to as- 
sume that this device should not be used for large 
right-to-left shunts. Indeed, in one case (1 of 20 in 
which the implanted device was not left in) of signif- 
icant right-to-left shunt the device had to be with- 
drawn because it increased the magnitude of the 
right-to-left shunt. A double-disc or an inverted-disc 
device already tested in animals is expected to 
address this problem (Sideris EB, Rao PS; unpub- 
lished observations). 
Echocardiographic assessment. Presence of good 
septal margin in several views (Fig. 1) is necessary for 
proper placement of the device. Patients with small 
septal rims are unlikely to have successful transcath- 
eter occlusion of their atria1 defects. In this study we 
used only such subjective criteria and did not pro- 
spectively make any measurements to solve this 
problem. Comparing the septal margins and margin/ 
atria1 septal defect ratio between groups of patients 
that had successful versus unsuccessful implantation 
of the device in future studies may help resolve this 
issue. 
Complications. The complications reported herein 
reflect the learning curve of the method. Indeed, this 
is the cumulative experience of 16 investigators/cen- 
ters. Most investigators underwent animal implan- 
tation training and were instructed in their first 
cases, but most required more independent experi- 
ence. Unbuttoning, the most common complication, 
occurred in 13 (7%) of 180 cases. In 12 of 13 cases, 
unbuttoning occurred with investigators just starting 
with the method, probably as a result of their hesita- 
tion to pull the occluder strongly and stretch the 
button loop when they were pushing the counteroc- 
eluder. Although there are several radiographic signs 
of good buttoning and the device can be retrieved 
before release, imperfections of the guidance system 
made this assessment inaccurate on some occasions. 
Although the unbuttoning complication does not 
frequently occur with experienced investigators, mi- 
nor modifications of the button loop were thought to 
be necessary to facilitate buttoning. A second small 
loop that keeps the radiopaque button straight with 
minor traction was introduced (Fig. 2). After this 
modification 65 device implantations were performed 
with only two unbuttonings. 
Most of the unbuttoned occluders (11 of 13) 
remained on the left atria1 side of the atria1 septum, 
well occluding the defect. In one case the device was 
totally embolized into the pulmonary artery after re- 
lease, most likely because of selection of too small an 
occluder, probably because of inadequate balloon 
sizing. All patients remained hemodynamically sta- 
ble after unbuttoning/embolization, and the surgical 
correction of the defect and removal of the device 
were undertaken at the same time. 
Nevertheless, 160 (89%) of 180 patients with an 
implanted device (or 160 [80%] of 200 patients with 
intent to close the defect) remained free of further 
intervention; their defects were well occluded. This 
success rate is expected to improve in the future. So 
far, the worst complication of the method is the need 
for surgery in nearly 11% of patients in whom the 
device was implanted. The need for surgical inter- 
vention was usually related to unbuttoning, and this 
problem appears to have been improved by the 
third-generation device. Consequently, the risk of 
unbuttoning is likely to be reduced, and therefore the 
requirement for surgical intervention may diminish. 
Comparison with other devices. The only other 
device that has undergone clinical trials comparable 
to the buttoned device is the Bard Clamshell Septal 
Occluder (USCI). Preliminary results24 and a sum- 
mary of the first 100 cases25 have been reported. Of 
the first 40 patients with intent to close,z4 34 (85 % ) 
underwent device implantation. Device embolization 
was noted in 2 (6%) of 34 patients. Residual shunts, 
evaluated in 19 patients 6.5 months after implanta- 
tion, were present in 7 (37 % ). Of’ the first 100 
patients”” with intent to occlude t,he atria1 septal de- 
fect, 93 (93? ) had the device implanted. Only 3 
(3.2%) device embolizations were reported.25 Com- 
plete closure by echo Doppler was stated to be in the 
range of 84% of the patients. These results are sim- 
ilar to those reported in this article on the buttoned 
device. However, the Bard Clamshell Occluder re- 
quires an 11F sheath for delivery in contrast to the 
buttoned device, which requires an 8F (9F for larger 
devices) sheath. In addition, an incidence of late 
fractures of one or more arms of the Clamshell device 
of approximately 30 % with embolization20> 11 has 
prompted the investigators to withdraw the device 
from clinical trials. 
Limitations. Although we are reasonably sure that 
our conclusions are valid, there are certain limita- 
tions to this study. The multiinstitutional nature of 
the study, by necessity, introduces some known and 
some unknown variables in the selection of patients 
and method of closure. In addition, the learning curve 
of the new investigators also adds to the problem. 
Unfortunately, only a certain percentage of pa- 
tients with atria1 septal defect are candidates for this 
method. Ostium primum defects, sinus venosus de- 
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fects, and secundum defects >25 mm could not be 
closed. Furthermore, a small number of patients with 
defects <25 mm could not be occluded because of a 
small left atrium, short septal length, lack of sup- 
portive tissue, or unusual location of the defect. One 
possibly remediable factor could be the ability of the 
operator to manipulate the device properly in a 
nonideal defect. It is likely that more than half of all 
secundum atria1 septal defects are suitable for tran- 
scatheter closure. Improvement of this method and 
the evolution of other transcatheter methods are ex- 
pected to improve the current management of pa- 
tients with cardiac defects. 
Conclusions. Buttoned devices were used to oc- 
clude secundum atria1 septal defects in 180 patients. 
Device dislodgment (7.8%) was the major complica- 
tion of this procedure. Although dislodgment re- 
quired transcatheter or surgical retrieval, the pa- 
tients were hemodynamically stable and underwent 
successful surgical correction. With increasing oper- 
ator experience and some improvement of the device 
design (third-generation), the unbuttoning compli- 
cation is likely to be reduced. The data we present 
suggest that transcatheter occlusion of the secundum 
atrial septal defect is feasible, relatively safe, and ef- 
fective in most cases. Transcatheter occlusion with 
the buttoned device appears to be a viable alternative 
to surgery for some patients with secundum atria1 
septal defect. 
SUMMARY 
Several devices are available for transcatheter oc- 
clusion of atria1 septal defect. This report describes 
the international experience with the buttoned de- 
vice. During a 4.5-year period ending in February 
1993,180 transcatheter atria1 septal defect occlusions 
were performed with the buttoned device. Patient 
age varied between 0.6 and 76 years and stretched 
atria1 defect diameter between 5 and 25 mm. The de- 
fects were closed with 25 to 50 mm devices delivered 
through 8F (148 patients) or 9F (32 patients) sheaths. 
Twelve patients were adults whose defects were 
closed to prevent recurrence of cerebrovascular acci- 
dents caused by presumed paradoxic embolism. In 
the remaining patients the atria1 defect was closed to 
treat the left-to-right shunt. The atria1 septal defects 
were effectively occluded as demonstrated by (1) de- 
crease in pulmonary-to-systemic flow ratio from 
2.1 f 0.6 (mean k SD) to 1.05 +- 0.1 (p < 0.01) by 
oximetry; (2) normalized Sz and disappearance of the 
diastolic murmur by auscultation; and (3) improve- 
ment in right ventricular volume overloading by 
echocardiogram. However, trivial to small shunts 
(45%) of 168 patients in whom such data are avail- 
able. Complications included unbuttoning in 13 and 
whole-device embolization in 1. All patients re- 
mained stable, and retrieval of the device and surgi- 
cal closure of the atria1 septal defect were accom- 
plished in 10 patients. Transcatheter retrieval was 
used in the remaining 4 patients. The incidence of 
unbuttoning, a major complication of the procedure, 
appeared to decrease with the increasing experience 
of the investigators and with device modification 
(third-generation). The follow-up duration varied 
between 1 month and 4 years. Six patients required 
surgery during the follow-up period. In the remain- 
ing patients (n = 160), clinical examination did not 
reveal signs of atria1 shunts. Color Doppler studies 
revealed either complete disappearance of the previ- 
ously demonstrated shunts or further diminution of 
their size. The results indicate that transcatheter oc- 
clusion of the atria1 septal defects with buttoned de- 
vices is feasible, relatively safe, and effective, and it 
appears to be a viable alternative to surgery for some 
patients with secundum atria1 septal defect. Compli- 
cations are infrequent and should improve with ex- 
perience. 
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